Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATREZZO Study
2020-000245-13Phase 2Active
- Sponsor
- SOLTI
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab, trastuzumab and vinorelbine in breast cancer (2 cohorts), sponsored by SOLTI. Primary endpoint: Overall response rate. Started Oct 2023; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-000245-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000245-13.